
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with Reimbursement from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/reimbursement/topic/21708/</link>
        <description>Articles tagged with Reimbursement from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>Orexigen, Vivus remain in weight-loss limbo</title>
          <description>Quarterly reports show that that the weight loss category remains a cool one, but studies indicate that even the best marketing plan will have to overcome payer and pricing issues.</description>
          <link>http://www.mmm-online.com/orexigen-vivus-remain-in-weight-loss-limbo/article/292704/</link>
          <pubDate>Thu, 09 May 2013 18:03:25 GMT</pubDate>
          <itunes:summary>Quarterly reports show that that the weight loss category remains a cool one, but studies indicate that even the best marketing plan will have to overcome payer and pricing issues.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Oncology lifts Roche&apos;s Q1, Lucentis finds new fans</title>
          <description>Roche&apos;s oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.</description>
          <link>http://www.mmm-online.com/oncology-lifts-roches-q1-lucentis-finds-new-fans/article/288379/</link>
          <pubDate>Thu, 11 Apr 2013 15:20:25 GMT</pubDate>
          <itunes:summary>Roche&apos;s oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Docs&apos; presidential preferences follow practice type</title>
          <description>Solo practitioners favor Mitt Romney over Barack Obama by a two-to-one ratio, a survey finds, suggesting that changes in reimbursement driven by Obamacare are driving physicians&apos; presidential preferences.</description>
          <link>http://www.mmm-online.com/docs-presidential-preferences-follow-practice-type/article/263204/</link>
          <pubDate>Thu, 11 Oct 2012 16:07:39 GMT</pubDate>
          <itunes:summary>Solo practitioners favor Mitt Romney over Barack Obama by a two-to-one ratio, a survey finds, suggesting that changes in reimbursement driven by Obamacare are driving physicians&apos; presidential preferences.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  